Neurogene Inc (NGNE)
Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological disorders. Its pipeline includes NGN-401, an adeno-associated virus 9-based candidate being studied in a Phase 1/2 trial for Rett syndrome, and NGN-101, a gene therapy program in a Phase 1/2 trial for CLN5 Batten disease. The company has licensing agreements with the University of Edinburgh, Virovek, Sigma-Aldrich, and Stanford University. Neurogene was founded in 2018 and is based in New York, New York. Neurogene common stock trades on the NASDAQ under the symbol NGNE.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NGNE
|
$25.27
|
-24.8% Downside
|
Overvalued
|
$80.43
|
139.4% Upside
|
Bargain
|
Fair
|
0.0%
|
November 23, 2026
|
3.1x
|
672.4 M
|
455.3 M
|
1.3%
|
56.6%
|
11.3
|
78.9%
|
